David Eby promises perinatal mental health unit at B.C. Women's Hospital - CBC

DUXBURY, Mass. — Hundreds of people came together in Duxbury Saturday to make sure parents struggling with their mental health know they don’t have to face it alone. Families and supporters gathered for the community’s second annual Postpartum Support International Climb, a walk aimed at raising awareness and money for perinatal mental health care. The event began at Pilgrim Church of Duxbury. For Emily Newton, director of PSI’s The Climb program, the mission is personal. “18 years ago when I had my first baby and didn’t quite feel like myself, I needed a safety net and I didn’t know how to make one,” Newton told Boston 25 News. Postpartum Support International provides support and resources for families experiencing mental health challenges during pregnancy and after childbirth. Its Climb program brings communities together across the country to raise awareness and support perinatal mental health care. Kelly Winter, a leader of the Duxbury event, said the local Climb began after she brought the idea to her church’s missions committee.0 of 8“I brought forward PSI and everyone really wanted to do one of these Climb events, and so we had our first one last year,” Winter said.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.